Top Markets
Coin of the day
Devonian Health Group Inc. Devonian Health Group Inc.

Devonian Health Group Inc.

DVHGF
Classifica tra le azioni #29820
Devonian Health Group Inc. specializes in the creation of botanical-based... Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing gastric or duodenal ulcers, Cleo-35 targeting hormonal acne in women, and a range of value-added dermo-cosmetic products. Beyond its own development efforts, Devonian acquires licenses for and distributes various pharmaceutical and health products. Furthermore, the company has established a strategic partnership with CannTx Life Sciences Inc. to collaborate on the development of cannabinoid-based pharmaceutical drugs. Devonian Health Group Inc. was founded in 2015 and is based in Québec, Canada.
Prezzo delle azioni
$7.00
Ultima sincronizzazione: 2026-08-17
Capitalizzazione di mercato
$19.47M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-35.19%
Paese
CA
Scambia Devonian Health Group Inc. (DVHGF)

Categoria

Rapporto P/B per Devonian Health Group Inc. (DVHGF)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Devonian Health Group Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Devonian Health Group Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
- -
KR